Niagen Bioscience Inc

NASDAQ:NAGE

Biotechnology

Healthcare
$1.94 +3.31%

+$0.11 today

Market cap
$153.64M
Beta
2.06
P/E (TTM)
14.9
EPS (TTM)
$0.23
52W Low $3.35High $14.69

Volume 0.52M

Average 0.86M

NAGE EBITDA Margin

EBITDA as a percentage of revenue.

Niagen Bioscience IncNASDAQ: NAGE

EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026

EBITDA Margin widens to 22.3%

EBITDA Margin was 22.3% in Q1 FY2026, up 4.0 pp from a year earlier. On a trailing-twelve-month basis it was 16.4%, up 1.5 pp year over year. Over 3 fiscal years it widened by 35.5 pp.

Context

  • EBITDA Margin widened in 3 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 4 analysts of 6.2% for the fiscal year ending Dec 2026, down from 15.2% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
22.3%+6.7 pp QoQ
Last fiscal yearDec 2025
15.2%+4.8 pp YoY
LTMMar 2026
16.4%+1.5 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+4.0 pp-8.9 pp-12.8 pp
1 year+4.8 pp-9.0 pp-13.8 pp
3 years+35.5 pp-5.6 pp-41.1 pp
5 years+4.2 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
15.2%
Year-over-year change
+4.8pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How NAGE compares with its peers on the latest reported figures

  • NAGE's LTM Mar 2026 EBITDA Margin of 16.4% is the 3rd highest of the 8 companies compared; the peer median is -101.1%.
  • Its year-over-year change of +1.5 pp is the 3rd highest of 7, against a peer median of -25.3 pp.
  • Over three fiscal years its change of +35.5 pp compares with a peer median of +89.5 pp.
NAGE Competitors Peer median
EBITDA Margin for NAGE and competitors
Company Period LTM level YoY 3-year change
ZVRAZevra Therapeutics, Inc.LTM Mar 2026114.9% +263.4 pp+343.9 pp
RIGLRigel Pharmaceuticals, Inc.LTM Mar 202643.8% +19.9 pp+89.5 pp
NAGENiagen Bioscience IncLTM Mar 202616.4% +1.5 pp+35.5 pp
AKBAAkebia Therapeutics, Inc.LTM Mar 2026-2.5% -5.1 pp+8.2 pp
KALVKalVista Pharmaceuticals, Inc.LTM Dec 2025-101.1% ——
PRTAProthena Corporation plcLTM Mar 2026-129.0% -45.6 pp-1804.0 pp
RGNXREGENXBIO Inc.LTM Mar 2026-261.2% -183.0 pp+138.5 pp
KROSKeros Therapeutics, Inc.LTM Mar 2026-267.4% -282.4 pp—
CRVSCorvus Pharmaceuticals, Inc.FY2025— ——
OLMAOlema Pharmaceuticals, Inc.FY2025— ——
Peer median (excluding NAGE) -101.1%-25.3 pp+89.5 pp

Competitors are the stored peer set for NAGE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue67.45M72.05M83.57M99.6M129.42M
Cost of Revenue25.96M29.25M32.79M38.01M46.23M
Gross Profit41.49M42.8M50.78M61.59M83.19M
Gross Margin61.5%59.4%60.8%61.8%64.3%
Research & Development3.83M4.83M4.96M6.02M6.33M
Selling, General & Admin64.73M56.6M51.42M47.84M62.56M
Operating Expenses68.56M61.43M56.38M53.86M68.89M
Depreciation & Amortization1.63M1.88M1.71M1.48M1.45M
EBITDA(25.45M)(14.66M)(3.23M)10.34M19.64M
EBITDA Margin-37.7%-20.3%-3.9%10.4%15.2%
Operating Income(27.07M)(18.63M)(5.6M)7.73M14.3M
Operating Margin-40.1%-25.9%-6.7%7.8%11.0%
Interest Income03K661K1.13M2.13M
Interest Expense55K0000
Other Income / Expenses(55K)2.09M661K1.13M3.9M
Income Before Tax(27.13M)(16.54M)(4.94M)8.86M18.19M
Pre-Tax Margin-40.2%-23.0%-5.9%8.9%14.1%
Income Tax Expense000305K810K
Net Income(27.13M)(16.54M)(4.94M)8.55M17.38M
Net Margin-40.2%-23.0%-5.9%8.6%13.4%
EPS (Basic)(0.40)(0.24)(0.07)0.100.22
EPS (Diluted)(0.40)(0.24)(0.07)0.110.20
Weighted Avg Shares67.19M68.92M70.54M85.42M79.18M
Weighted Avg Shares (Diluted)67.19M69.73M74.99M79.72M85.44M

Niagen Bioscience Inc

NASDAQ:NAGE

Intrinsic Alpha fair value

Locked

Current Price

$1.94

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.